TY - JOUR
T1 - Valuation of EQ-5D-5L health states
T2 - a comparison of seven Asian populations
AU - Wang, Pei
AU - Liu, Gordon G.
AU - Jo, Min woo
AU - Purba, Frederick Dermawan
AU - Yang, Zhihao
AU - Gandhi, Mihir
AU - Pattanaphesaj, Juntana
AU - Ahn, Jeonghoon
AU - Wong, Eliza Lai yi
AU - Shafie, Arsul A.
AU - Busschbach, Jan J.V.
AU - Luo, Nan
N1 - Funding Information:
This study was supported by the Health & Medical Research Fund from the Food and Health Bureau of Hong Kong, Hong Kong Special Administrative Region (HKSAR) (grant number: HMRF11120491) and EuroQol Research Foundation.
Funding Information:
Jan Busschbach, Nan Luo and Zhihao Yang are members of the EuroQol Group. All authors received research grants from the EuroQol Research Foundation as principal or co-principal investigators. This study was supported by the Health & Medical Research Fund from the Food and Health Bureau of Hong Kong, Hong Kong Special Administrative Region (HKSAR) (grant number: HMRF11120491) and EuroQol Research Foundation.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/7/4
Y1 - 2019/7/4
N2 - Objectives: To compare the time trade-off (TTO) utility values of EQ-5D-5L health states elicited from different general populations in Asia. Methods: We analyzed the TTO data from seven Asian EQ-5D-5L valuation studies in which utility values of 86 EQ-5D-5L health states were elicited from general population samples. An eight-parameter multiplicative regression model including five dimension parameters (mobility [MO], self-care, usual activities [UA], pain/discomfort, anxiety/depression) and three level parameters (level 2 [L2], level 3 [L3], and level 4 [L4]) was used to model the data from each of the populations. The model coefficients were compared to understand how the valuations of EQ-5D-5L health states differ. Results: For dimension parameters, Korea and Indonesia generally had the highest and lowest values among the populations, respectively; UA and MO commonly had the highest and lowest values among the parameters, respectively. For level parameters, Singapore and Korea generally had the highest and lowest values, respectively; L2 showed less variance compared to L3 and L4. Koreans, Indonesians, and Singaporeans appeared to have different health preferences compared with other populations. Conclusion: Utility values of EQ-5D-5L health states differ among Asian populations, suggesting that each health system should establish and use its own value set.
AB - Objectives: To compare the time trade-off (TTO) utility values of EQ-5D-5L health states elicited from different general populations in Asia. Methods: We analyzed the TTO data from seven Asian EQ-5D-5L valuation studies in which utility values of 86 EQ-5D-5L health states were elicited from general population samples. An eight-parameter multiplicative regression model including five dimension parameters (mobility [MO], self-care, usual activities [UA], pain/discomfort, anxiety/depression) and three level parameters (level 2 [L2], level 3 [L3], and level 4 [L4]) was used to model the data from each of the populations. The model coefficients were compared to understand how the valuations of EQ-5D-5L health states differ. Results: For dimension parameters, Korea and Indonesia generally had the highest and lowest values among the populations, respectively; UA and MO commonly had the highest and lowest values among the parameters, respectively. For level parameters, Singapore and Korea generally had the highest and lowest values, respectively; L2 showed less variance compared to L3 and L4. Koreans, Indonesians, and Singaporeans appeared to have different health preferences compared with other populations. Conclusion: Utility values of EQ-5D-5L health states differ among Asian populations, suggesting that each health system should establish and use its own value set.
KW - Asia
KW - EQ-5D
KW - comparison
KW - utility
KW - valuation
UR - http://www.scopus.com/inward/record.url?scp=85058842723&partnerID=8YFLogxK
U2 - 10.1080/14737167.2019.1557048
DO - 10.1080/14737167.2019.1557048
M3 - Article
C2 - 30523723
AN - SCOPUS:85058842723
SN - 1473-7167
VL - 19
SP - 445
EP - 451
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 4
ER -